Incyte Corp (INCY)
82.10
+3.08 +3.90%
NASDAQ
Feb 24, 13:03
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 2.667B |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | -1.40 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | -295.70M |
Profitability | |
Gross Profit Margin (Quarterly) | 95.40% |
Profit Margin (Quarterly) | 18.98% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0% |
Price and Valuation | |
Market Cap | 18.05B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 6.736 |
PE Ratio | -- |
Price to Book Value | 6.912 |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | 0.00 |
Free Cash Flow (Quarterly) | 55.89M |
Return on Equity | Upgrade |
View All INCY News
News
-
WireHeadlineTime (ET)
-
MT Newswires02/22 11:02
-
Yahoo02/22 09:18
-
Yahoo02/22 08:00
-
SA Breaking News02/19 09:26
-
MT Newswires02/19 08:42
-
Yahoo02/19 08:00
-
MT Newswires02/11 09:38
-
Yahoo02/11 09:13
-
Yahoo02/11 08:00
-
Yahoo02/11 03:06
-
Yahoo02/10 11:57
-
Yahoo02/10 10:05
-
SA Breaking News02/10 09:05
-
MT Newswires02/10 08:16
-
MT Newswires02/10 08:13
-
MT Newswires02/10 07:29
-
MT Newswires02/09 15:35
-
Yahoo02/09 14:00
-
Yahoo02/09 13:30
-
MT Newswires02/09 10:03
View All Events
Events
Date | Type | Description |
---|---|---|
05/05/2021 | Earnings | Incyte Corp First Quarter Earnings Results for 2021 |
05/05/2021 | Misc | Incyte Corp First Quarter Earnings Conference Call for 2021 |
02/09/2021 07:00 EST | Earnings | Incyte Corp Fourth Quarter Earnings Results for 2020 |
02/09/2021 08:00 EST | Misc | Incyte Corp Fourth Quarter Earnings Conference Call for 2020 |
02/09/2021 | Misc | Incyte Corp Annual Report for 2020 |
11/05/2020 | Earnings | Incyte Corp Third Quarter Earnings Result for 2020 |
11/05/2020 08:00 EST | Misc | Incyte Corp Third Quarter Earnings Conference Call for 2020 |
08/04/2020 08:00 EDT | Misc | Incyte Corp Second Quarter Earnings Conference Call for 2020 |
08/04/2020 07:00 EDT | Earnings | Incyte Corp Second Quarter Earnings Results for 2020 |
05/26/2020 13:00 EDT | Misc | Incyte Corp Annual General Meeting for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.incyte.com
- Investor Relations URL: http://www.incyte.com/ir/investor-overview.aspx
- HQ State/Province: Delaware
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: May. 05, 2021
- Last Earnings Release: Feb. 09, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 82.10 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Top Fund Holders
Symbol | Name | Weighting |
---|---|---|
TMIFX | Transamerica Mid Cap Growth R4 | 3.50% |
BBH | VanEck Vectors Biotech ETF | 3.12% |
ARKG | ARK Genomic Revolution ETF | 2.45% |
VGHCX | Vanguard Health Care Inv | 1.86% |
ZUH.TO | BMO Eq Wght US HlthCare Hdgd to CAD ETF | 1.77% |
TDB875 | TD Health Sciences Fund - O | 1.71% |
THISX | T. Rowe Price Health Sciences I | 1.43% |
IBB | iShares Nasdaq Biotechnology ETF | 1.36% |
ATL1635 | Renaissance Global Health Care Class F | 1.33% |
VCHSX | VALIC Company I Health Sciences | 1.31% |
BIB | ProShares Ultra Nasdaq Biotechnology | 1.16% |
HQH | Tekla Healthcare Investors | 0.84% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- INCY Tweets Stocktwits
Advertisement